bluebird bio Inc (NASDAQ:BLUE) just announced Phase 1 results of bb2121, the BCMA CAR-T therapy, in patients with relapsed /refractory multiple myeloma that …
bluebird bio Inc (NASDAQ:BLUE) announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief …
The biotech-verse is in full upheaval mode as Heat Biologics Inc (NASDAQ:HTBX) shares nosedive following disheartening Phase II results in bladder cancer and …
bluebird bio Inc (NASDAQ:BLUE) shares are surging 25% after releasing interim results from the firm’s Phase 1 trial of its anti-BCMA CAR T …
bluebird bio Inc (NASDAQ:BLUE) announced that interim data from its ongoing Phase 1 clinical study of bb2121, the company’s investigational anti-BCMA CAR T cell …
Yesterday, Piper Jaffray analyst Joshua Schimmer hosted an investor dinner with bluebird bio Inc (NASDAQ:BLUE) management ahead of his healthcare conference. Following the …
News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors running for the hills and have left shares …
bluebird bio Inc (NASDAQ:BLUE) reported business highlights and financial results for the third quarter ended September 30, 2016. “In recent months, we have …
On October 13th, bluebird bio Inc (NASDAQ:BLUE) hosted a Research and Development (R&D) Day shining light on its newly implemented process and manufacturing …
Following bluebird bio Inc’s (NASDAQ:BLUE) first research and development (R&D) meeting, Cowen top analyst Eric Schmidt shares insight on the firm’s preclinical strides …
